Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Free Cash Flow (2019 - 2025)

Historic Free Cash Flow for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to -$156.9 million.

  • Avidity Biosciences' Free Cash Flow fell 13304.71% to -$156.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$592.3 million, marking a year-over-year decrease of 21417.95%. This contributed to the annual value of -$307.9 million for FY2024, which is 14976.15% down from last year.
  • Per Avidity Biosciences' latest filing, its Free Cash Flow stood at -$156.9 million for Q3 2025, which was down 13304.71% from -$203.0 million recorded in Q2 2025.
  • In the past 5 years, Avidity Biosciences' Free Cash Flow registered a high of $15.6 million during Q4 2023, and its lowest value of -$203.0 million during Q2 2025.
  • Moreover, its 5-year median value for Free Cash Flow was -$40.0 million (2022), whereas its average is -$60.9 million.
  • As far as peak fluctuations go, Avidity Biosciences' Free Cash Flow skyrocketed by 13905.69% in 2023, and later tumbled by 76368.46% in 2024.
  • Over the past 5 years, Avidity Biosciences' Free Cash Flow (Quarter) stood at -$27.9 million in 2021, then tumbled by 43.4% to -$40.0 million in 2022, then surged by 139.06% to $15.6 million in 2023, then crashed by 763.68% to -$103.8 million in 2024, then tumbled by 51.16% to -$156.9 million in 2025.
  • Its Free Cash Flow was -$156.9 million in Q3 2025, compared to -$203.0 million in Q2 2025 and -$128.6 million in Q1 2025.